Subject(s)
Aortic Valve Stenosis , Heart Valve Prosthesis Implantation , Heart Valve Prosthesis , Mitral Valve Insufficiency , Transcatheter Aortic Valve Replacement , Aortic Valve/diagnostic imaging , Aortic Valve/surgery , Aortic Valve Stenosis/surgery , Calcium , Humans , Mitral Valve Insufficiency/surgery , Treatment OutcomeABSTRACT
In patients who underwent transcatheter aortic valve implantation (TAVI), vascular disease is associated with increased risk of mortality. Thoracic aortic calcification (TAC), an objective surrogate of vascular disease, could be a predictor of mortality after TAVI. We aimed to analyze the association between TAC burden and 1-year all-cause mortality in patients who underwent TAVI in a US population. From July 2015 through July 2017, a retrospective review of TAVI procedures was performed at Baylor Scott & White-The Heart Hospital, Plano, Texas. Patients were analyzed for comorbidities, cardiac risk factors, and 30-day and 1-year all-cause mortality. Restricted cubic splines analysis was used to define low, moderate, and high TAC categories. The association between TAC and survival was evaluated using unadjusted and adjusted Cox models. A total of 431 TAVI procedures were performed, of which TAC was measured in 374 (81%) patients. Median (interquartile range) age was 82 (77, 87) years, and 51% were male. Median (interquartile range) STS PROM was 5.6 (4.1, 8.2) %. Overall 30-day and 1-year all-cause mortality was 1% and 10%, respectively. TAC was categorized as low (<1.6 cm3), moderate (1.6 to 2.9 cm3), and high (>2.9 cm3). At 1 year, all-cause mortality was 16% in patients with high TAC compared with 6% in the low and moderate TAC categories (pâ¯=â¯0.008). Unadjusted and adjusted Cox regression analysis showed a significant increase in mortality for patients with high TAC compared with low TAC (hazard ratio 2.98, 95% confidence interval [1.34-6.63]), but not significant compared with moderate TAC group. TAC is a predictor of late mortality after TAVI. In conclusion, adding TAC to preoperative evaluation may provide an objective, reproducible, and potentially widely available tool that can help in shared decision-making.
Subject(s)
Aorta, Thoracic/diagnostic imaging , Aortic Diseases/diagnosis , Aortic Valve Stenosis/surgery , Calcinosis/diagnosis , Calcium/metabolism , Multidetector Computed Tomography/methods , Transcatheter Aortic Valve Replacement/methods , Aged , Aged, 80 and over , Aorta, Thoracic/metabolism , Aortic Diseases/metabolism , Aortic Valve/diagnostic imaging , Aortic Valve/surgery , Aortic Valve Stenosis/diagnosis , Calcinosis/epidemiology , Calcinosis/metabolism , Female , Follow-Up Studies , France/epidemiology , Humans , Male , Registries , Retrospective Studies , Risk Factors , Survival Rate/trendsABSTRACT
This study was performed to investigate the prevalence and impact on survival of baseline mitral stenosis (MS) in patients who underwent transcatheter aortic valve implantation (TAVI) due to the presence of severe symptomatic aortic stenosis. This retrospective study included 928 consecutive patients with severe, symptomatic aortic stenosis who underwent TAVI in 2 institutions, from January 2012 to August 2016. Mean follow-up was 40.8 ± 13.9 months. Based on the mean mitral gradient (MMG) at baseline, 3 groups were identified: MMG <5 mm Hg (nâ¯=â¯737, 81.7%); MMG ≥5 and <10 mm Hg (nâ¯=â¯147, 16.3%); MMG ≥10 mm Hg (nâ¯=â¯17, 1.9%). These latter were more frequently women, with a smaller body surface area, a higher prevalence of atrial fibrillation, chronic obstructive pulmonary disease, and previous history of coronary-artery bypass graft/percutaneous coronary intervention. At baseline, patients with MMG ≥10 mm Hg compared with ≥5 and <10 mm Hg and <5 mm Hg patients had a lower mitral valve area (2.4 ± 0.94 vs 2.1 ± 0.86 vs 1.5 ± 0.44 cm2), a lower prevalence of MR ≥2+ (5.9% vs 28.6% and 15.6%, p <0.0001), a higher prevalence of severe mitral annular calcium (70.6% vs 45.6% and 13.0%, p <0.0001) and a higher systolic pulmonary arterial pressure (50.6 ± 12.1 vs 47.2 ± 14.5 and 41.6 ± 14.4, p <0.0001). Despite the low prevalence of MMG ≥10 mm Hg, these patients had higher 5-year mortality compared with the other groups (adjusted hazard ratio 2.91, 95% confidence interval 1.17 to 7.20, pâ¯=â¯0.02). In conclusion, severe calcific MS is uncommon in patients who underwent TAVI. Its presence is associated with higher long-term mortality whereas moderate MS is not.
Subject(s)
Aortic Valve Stenosis/surgery , Mitral Valve Stenosis/etiology , Mitral Valve/diagnostic imaging , Transcatheter Aortic Valve Replacement , Ventricular Function, Left/physiology , Aged , Aged, 80 and over , Aortic Valve/surgery , Aortic Valve Stenosis/complications , Aortic Valve Stenosis/diagnosis , Cardiac Catheterization , Echocardiography , Female , Follow-Up Studies , Humans , Male , Mitral Valve Stenosis/epidemiology , Prevalence , Retrospective Studies , Risk Factors , Severity of Illness Index , Survival Rate/trends , Texas/epidemiology , Time Factors , Treatment OutcomeABSTRACT
BACKGROUND: The incidence of leaflet thrombosis after transcatheter aortic valve replacement (TAVR) with active surveillance by four-dimensional computed tomography (4DCT) ranges from 7% to 14%. The incidence of leaflet thrombosis when 4DCT is performed for clinical and echocardiographic indications is unknown. METHODS: All patients with prior TAVR or surgical aortic valve replacement (SAVR) who underwent evaluation between October 2015 and January 2017 at our institution and had clinical or echocardiographic indications of leaflet thrombosis were evaluated by 4DCT. Indications for 4DCT by echocardiography included (1) interval increase in mean gradient of 10 mm Hg or more, (2) interval decrease in ejection fraction of 10% or more, (3) thrombus seen on transthoracic echocardiography, (4) persistent or increasing paravalvular leak, or (5) valve dehiscence or thickened leaflets seen on transthoracic echocardiography. Clinical indicators were (1) stroke, (2) transient ischemic attack, or (3) new or worsening heart failure. RESULTS: During the study period, 612 patients underwent TAVR, and 101 patients (55 TAVR; 46 SAVR) met the criteria for 4DCT imaging. Leaflet thrombosis was seen in 17 of 55 TAVR patients (30.9%) and 15 of 46 SAVR patients (32.6%). Follow-up imaging with 4DCT after treatment with anticoagulation showed improvement or resolution in thrombus burden and leaflet excursion in all TAVR patients and in two-thirds of SAVR patients. CONCLUSIONS: One-third of patients with clinical or echocardiographic indications suggestive of leaflet thrombosis were found to have evidence of leaflet thrombosis using 4DCT. This allowed tailored anticoagulation therapy with resolution of the thrombus in most patients and avoiding unnecessary anticoagulation in the remaining two-thirds of patients.
Subject(s)
Aortic Valve/surgery , Bioprosthesis , Four-Dimensional Computed Tomography , Heart Valve Diseases/diagnostic imaging , Postoperative Complications/diagnostic imaging , Thrombosis/diagnostic imaging , Transcatheter Aortic Valve Replacement , Aged , Aged, 80 and over , Echocardiography , HumansABSTRACT
Cardiac computed tomography angiography (CCTA) is the gold standard for accurately sizing the aortic valve annulus prior to aortic valve replacement. A reduction of contrast volume administered for CCTA, without sacrificing image quality, is desirable. Signal-to-noise ratio represents final CCTA image quality. Consecutive patients referred to CCTA for aortic valve annulus sizing were retrospectively analyzed. Patients were grouped into a low-dose contrast (LDCT) group and traditional dose contrast (TDCT) group. In the LDCT group, contrast dose was <50% of the maximal allowable dose (3.7 × estimated glomerular filtration rate). Guided by a time-density curve, the contrast was administered in a two-stage infusion, and retrospectively gated images were acquired with a 64-multidetector computed tomography scanner. Out of 123 patients (age 80 ± 9 years; 46% female), 65 (52.9%) underwent LDCT and 58 (47.2%) underwent TDCT. Contrast volume was significantly lower in the LDCT group (LDCT 41.2 ± 9.8 vs TDCT 76.2 ± 14.2 mL; P < 0.001). The signal-to-noise ratio of the aortic root was 10.4 ± 4.1 for the LDCT group and 8.4 ± 3.3 for the TDCT group (P = 0.004). Aortic root dimensions could be measured in both LDCT and TDCT groups. In conclusion, LDCT with 64-slice CCTA can effectively size the aortic valve annulus to direct aortic valve replacement while offering reduced contrast exposure.
ABSTRACT
AIMS: Calcified aortic stenosis (AS) and mitral annular calcification (MAC) have certain similar etiology and pathophysiological mechanisms. MAC is frequently encountered in pre-procedural computed tomography (CT) imaging of patients that undergo transcatheter aortic valve replacement (TAVR), but its prognostic implications for these patients have not been thoroughly investigated. This study sought to evaluate the prevalence of MAC among patients with severe AS and to assess the clinical implications of MAC on these patients during and following TAVR. METHODS AND RESULTS: Consecutive patients that underwent TAVR were compared according to the existence of MAC and its severity in pre-TAVR CT scans. From the entire cohort of 761 patients, 49.3% had MAC, and 50.7% did not have MAC. Mild MAC was present in 231 patients (30.4%), moderate MAC in 72 patients (9.5%), and severe MAC in 72 patients (9.5%). Thirty-day mortality and major complications were similar between patients with and without MAC. In a multivariable survival analysis, severe MAC was found to be an independent strong predictor of overall mortality following TAVR (all-cause mortality: hazards ratio [HR] 1.95, 95% confidence interval [CI] 1.24-3.07, P = 0.004; cardiovascular mortality: HR 2.35, 95% CI 1.19-4.66; P = 0.01). Severe MAC was also found to be an independent strong predictor of new permanent pacemaker implantation (PPI) after TAVR (OR 2.83, 95% CI 1.08-7.47; P = 0.03). CONCLUSION: Half of the patients with severe AS evaluated for TAVR were found to have MAC. Severe MAC is associated with increased all-cause and cardiovascular mortality and with conduction abnormalities following TAVR and should be included in future risk stratification models for TAVR.
Subject(s)
Aortic Valve Stenosis/complications , Mitral Valve Insufficiency/complications , Transcatheter Aortic Valve Replacement/methods , Aged, 80 and over , Aortic Valve/pathology , Aortic Valve/surgery , Aortic Valve Stenosis/mortality , Aortic Valve Stenosis/surgery , Calcinosis/complications , Calcinosis/mortality , Calcinosis/surgery , Female , Humans , Male , Mitral Valve/surgery , Mitral Valve Insufficiency/mortality , Mitral Valve Insufficiency/surgery , Postoperative Complications/etiology , Postoperative Complications/mortality , Transcatheter Aortic Valve Replacement/adverse effects , Transcatheter Aortic Valve Replacement/mortality , Treatment Outcome , Vascular Calcification/complications , Vascular Calcification/mortality , Vascular Calcification/surgerySubject(s)
Aortic Valve Stenosis/diagnostic imaging , Aortic Valve/diagnostic imaging , Echocardiography , Heart Ventricles/diagnostic imaging , Patient Care Team , Tomography, X-Ray Computed , Aortic Valve/physiopathology , Aortic Valve Stenosis/physiopathology , Female , Heart Ventricles/physiopathology , Humans , Male , Predictive Value of Tests , Reproducibility of Results , Severity of Illness IndexABSTRACT
A major concern regarding transcatheter aortic valve replacement (TAVR) is leaflet thrombosis. Four-dimensional computed tomography (4D-CT) is the preferred imaging modality to evaluate patients with suspected valve thrombosis. To date, the abnormal findings visualized by 4D-CT suggestive of leaflet thrombosis have lacked pathologic confirmation from a surgically explanted valve in a surviving patient. Herein, we provide pathologic confirmation of thrombus formation following surgical explantation of a thrombosed TAVR prosthesis that was initially identified by 4D-CT.
ABSTRACT
Mitral annular calcification (MAC) is a chronic degenerative process at the fibrous base of the mitral valve. It is a feared diagnosis in the context of mitral valve operations because of the risk of severe adverse events such as atrioventricular disruption, injury to the circumflex artery during debridement, and difficult placement of annular sutures. We report a series of 3 consecutive female patients with severe circular MAC who underwent successful mitral valve replacement through a lateral minithoracotomy with use of an inverted transcatheter aortic valve.
Subject(s)
Aortic Valve/surgery , Calcinosis/surgery , Cardiac Catheterization/methods , Heart Valve Prosthesis Implantation/methods , Mitral Valve Insufficiency/surgery , Mitral Valve/surgery , Aged, 80 and over , Aortic Valve/diagnostic imaging , Calcinosis/diagnosis , Echocardiography, Three-Dimensional , Female , Humans , Mitral Valve/diagnostic imaging , Mitral Valve Insufficiency/diagnosis , Tomography, X-Ray ComputedABSTRACT
Coronary artery disease (CAD) mortality has been declining in the United States and in regions where health care systems are relatively advanced. Still, CAD remains the number one cause of death in both men and women in the United States, and coronary events have increased in women. Many traditional risk factors for CAD are related to lifestyle, and preventative treatment can be tailored to modifying specific factors. Novel risk factors also may contribute to CAD. Finally, as the risk for CAD is largely understood to be inherited, further genetic testing should play a role in preventative treatment of the disease.
Subject(s)
Aortic Valve Stenosis/therapy , Aortic Valve/pathology , Cardiac Catheterization/instrumentation , Heart Valve Prosthesis Implantation/instrumentation , Heart Valve Prosthesis , Imaging, Three-Dimensional , Magnetic Resonance Imaging , Aged , Aged, 80 and over , Aortic Valve Stenosis/pathology , Female , Heart Valve Prosthesis Implantation/methods , Humans , Image Interpretation, Computer-Assisted , Male , Predictive Value of Tests , Prospective Studies , Prosthesis Design , Severity of Illness Index , Treatment OutcomeABSTRACT
Coronary artery disease (CAD) mortality has been declining in the United States and in regions where health care systems are relatively advanced. Still, CAD remains the number one cause of death in both men and women in the United States, and coronary events have increased in women. Many traditional risk factors for CAD are related to lifestyle, and preventative treatment can be tailored to modifying specific factors. Novel risk factors also may contribute to CAD. Finally, as the risk for CAD is largely understood to be inherited, further genetic testing should play a role in preventative treatment of the disease.
Subject(s)
Coronary Artery Disease/epidemiology , Risk Assessment/methods , Global Health , Humans , Morbidity/trends , Risk Factors , Survival Rate/trendsABSTRACT
OBJECTIVE: To compare the use of regadenoson to adenosine for measurement of fractional flow reserve (FFR). BACKGROUND: FFR is an accepted method to assess the functional significance of intermediate coronary artery stenoses and uses adenosine to induce maximal hyperemia. The use of the selective A2a receptor agonist regadenoson for FFR is not established. METHODS: Fifty-seven patients undergoing clinically indicated FFR assessment of intermediate coronary stenoses were included. For the initial assessment of FFR, hyperemia was achieved by a standard intravenous adenosine infusion (140 mcg/kg/min). After a washout period of 10 min, FFR was reassessed using regadenoson as a single 0.4 mg intravenous bolus. FFR measurements were recorded at baseline and following maximal hyperemia with both agents. RESULTS: Mean age was 57 ± 8 years and 47 were male. Sixty coronary lesions were evaluated and were located in the left anterior descending in 34, the left circumflex in 9, right coronary in 15, and left main coronary artery in 2. Mean ( ± SD) FFR following adenosine and regadenoson was 0.79 ( ± 0.09) and 0.79 (±0.09), respectively, P = NS. Time to FFR nadir was shorter with regadenoson compared to adenosine, 36.6 ± 24 versus 66 ± 0.19 sec, P < 0.0001, respectively. No patients experienced any significant side effects related to regadenoson. CONCLUSIONS: Regadenoson is a viable alternative to intravenous adenosine for achieving maximal hyperemia during FFR assessment. Compared to adenosine, regadenoson has a similar hemodynamic response, achieves more rapid hyperemia, is easier to use, and has an excellent side-effect profile.
Subject(s)
Adenosine A2 Receptor Agonists , Adenosine , Cardiac Catheterization , Coronary Stenosis/diagnosis , Fractional Flow Reserve, Myocardial , Purines , Pyrazoles , Vasodilator Agents , Adenosine/administration & dosage , Adenosine/adverse effects , Adenosine A2 Receptor Agonists/administration & dosage , Adenosine A2 Receptor Agonists/adverse effects , Aged , Coronary Angiography , Coronary Stenosis/physiopathology , Female , Hemodynamics , Humans , Hyperemia/physiopathology , Infusions, Intravenous , Injections, Intravenous , Male , Middle Aged , Predictive Value of Tests , Prognosis , Purines/administration & dosage , Purines/adverse effects , Pyrazoles/administration & dosage , Pyrazoles/adverse effects , Reproducibility of Results , Severity of Illness Index , Vasodilator Agents/administration & dosage , Vasodilator Agents/adverse effectsABSTRACT
Pseudoaneurysms (PAs) of arteries in the lower extremities are uncommon. In most cases, a PA of the common femoral artery develops following percutaneous access and treatment with ultrasound guided thrombin injection achieves success rates approaching 98%. In contrast, the management of a PA of the distal leg vessels is more complex and may require additional endovascular and/or surgical treatments. We present a case of a recalcitrant PA involving the distal peroneal artery that developed following blunt trauma in a patient with Hemophilia B who failed ultrasound guided thrombin injection, para-aneurysmal saline injection and required two coil embolization procedures. Our observations suggest that Factor IX supplementation combined with aggressive coil embolization is the most effective treatment approach.
Subject(s)
Aneurysm, False/therapy , Factor IX/therapeutic use , Femoral Artery/surgery , Hemophilia B/therapy , Thrombin/therapeutic use , Adult , Aneurysm, False/complications , Aneurysm, False/diagnosis , Aneurysm, False/diagnostic imaging , Femoral Artery/diagnostic imaging , Hemophilia B/complications , Humans , Male , Thrombin/administration & dosage , Treatment Outcome , Ultrasonography, Interventional/methodsSubject(s)
Cardiac Catheterization/instrumentation , Coronary Sinus/diagnostic imaging , Mitral Valve Annuloplasty/instrumentation , Mitral Valve Insufficiency/therapy , Tomography, X-Ray Computed , Cardiac Catheterization/adverse effects , Equipment Design , Humans , Mitral Valve Annuloplasty/adverse effects , Mitral Valve Insufficiency/diagnostic imaging , Patient Selection , Predictive Value of Tests , Treatment OutcomeABSTRACT
RATIONALE AND OBJECTIVES: Cardiac computed tomography is increasingly being used to assess the degree of stenosis in coronary arteries. It has been shown in multiple studies to have high negative predictive value for obstructive disease compared to invasive cardiac catheterization (ICA). However, calcified segments are interpreted differently in each study. The aim of this study was to examine the association of calcified plaques on multi-detector row cardiac computed tomography (MDCT) with the degree of stenosis on ICA. MATERIALS AND METHODS: A total of 129 consecutive patients who underwent coronary evaluation on MDCT and also underwent ICA within 1 month of MDCT were included in the study. Each segment in the coronary artery was classified as mixed, calcified, or noncalcified. All segments with calcified plaque were evaluated, further classifying them as mild, moderate, or severe, and obstructive disease on ICA was used as the reference standard, in a blinded fashion. RESULTS: The average age of the patients was 60.8 9.5 years. A total of 379 calcified segments were included in the study. Among these segments, 363 (95.8%) were found to be nonobstructive (<70% stenosis) on ICA. Calcifications were categorized as mild, moderate, and severe in 283 (74.7%), 58 (15.3%), and 38 (10.0%) segments, respectively. When calcium was incomplete in the cross-section of the lumen (mild or moderate calcification), 98.5% of these segments (336 of 341) were associated with nonobstructive disease, decreasing to 71% with severe calcification. CONCLUSION: Calcified plaques seen on MDCT were commonly associated with nonobstructive disease on invasive angiography. Increasing focal calcification increased the likelihood of obstructive disease, but only 29% of severe segments were associated with significant obstructive disease.